Bright Minds Biosciences Inc. (DRUG) shares rose 22.35%, trading at $97.89, up $17.88, following the company's announcement of positive topline results from its Phase 2 clinical trial. The rally came after Bright Minds reported that its investigational compound, BMB-101, met the primary efficacy endpoint...
Bright Minds Biosciences Inc. (DRUG), Tuesday announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial, evaluating BMB-101 in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies. BMB-101 met its primary efficacy endpoints by demonstrating...
Bright Minds Biosciences Inc. (DRUG), a clinical-stage biotechnology company, announced that it will host a conference call and live webcast at 8:00 AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 dubbed the BREAKTHROUGH study in patients with drug-resistant Absence...
Bright Minds Biosciences (DRUG) Tuesday reported that BMB-101, its selective 5-HT2C Gq-biased agonist, completely abolished drop seizures in the DBA/2 mouse model of epilepsy.
Bright Minds Biosciences, Inc. (DRUG), a company focused on drug-resistant epilepsy, depression, and other central nervous system disorders, said on Tuesday that it has appointed Stephen D. Collins as Chief Medical Officer with immediate effect. The company has also announced that Mark A. Smith will...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.